Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study)

[1]  Fei Wang,et al.  Breast Cancer Awareness and Association with Frequency of Screening Among Women — China, 2020 , 2023, China CDC weekly.

[2]  R. Zheng,et al.  Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Female Breast Cancer — China, 2003–2017 , 2023, China CDC weekly.

[3]  Z. Fan,et al.  The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012) , 2023, Frontiers in Public Health.

[4]  R. Gelber,et al.  Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jason J. Liu,et al.  Young adult cancer incidence trends in Taiwan and the U.S. from 2002 to 2016. , 2022, Cancer epidemiology.

[6]  L. Testa,et al.  Breast cancer trends in women younger than 40 years in Brazil. , 2022, Cancer epidemiology.

[7]  Weidong Wei,et al.  Comparison of the Characteristics and Prognosis Between Very Young Women and Older Women With Breast Cancer: A Multi-Institutional Report From China , 2022, Frontiers in Oncology.

[8]  Lixi Li,et al.  Breast Cancer in Chinese Females Aged 25 Years and Younger , 2021, Journal of oncology.

[9]  A. Glas,et al.  70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. , 2021, The Lancet. Oncology.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  X. An,et al.  Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. , 2020, JAMA.

[12]  M. Ceppi,et al.  Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. , 2020, European journal of cancer.

[13]  Jie He,et al.  Cancer registration in China and its role in cancer prevention and control. , 2020, The Lancet. Oncology.

[14]  A. Kwong,et al.  Young onset breast cancer in Southern China - a 5-year clinico-pathological study from a multi-centre database. , 2020, Cancer treatment and research communications.

[15]  Jin-hai Tang,et al.  Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Su,et al.  Introduction of a multicenter online database for non-metastatic breast cancer in China , 2020, Science China Life Sciences.

[17]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[18]  R. Gelber,et al.  Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Jiong Wu,et al.  Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999−2017 , 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[20]  Virginia G Kaklamani,et al.  Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. , 2019, The New England journal of medicine.

[21]  J. Lee,et al.  Insights Into Breast Cancer in the East vs the West: A Review. , 2019, JAMA oncology.

[22]  Zhi-an Li,et al.  Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer , 2018, Medicine.

[23]  Wen-na Wang,et al.  Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China , 2018, International journal of cancer.

[24]  E. Winer,et al.  Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer , 2018, The New England journal of medicine.

[25]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[26]  R. Gelber,et al.  Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Hai-long Chen,et al.  Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database , 2016, PloS one.

[28]  O. Olopade,et al.  Effect of BRCA germline mutations on breast cancer prognosis , 2016, Medicine.

[29]  Rulla M Tamimi,et al.  Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[31]  A. Schneeweiss,et al.  Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials , 2015, Breast Cancer Research and Treatment.

[32]  S. Barni,et al.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.

[33]  I. Tengrup,et al.  Age at diagnosis in relation to survival following breast cancer: a cohort study , 2015, World Journal of Surgical Oncology.

[34]  P. Rosenberg,et al.  A Web Tool for Age–Period–Cohort Analysis of Cancer Incidence and Mortality Rates , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[35]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[36]  A. Valachis,et al.  Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis , 2014, Breast Cancer Research and Treatment.

[37]  D. Altman,et al.  Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. , 2013, Journal of the National Cancer Institute.

[38]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[39]  V. Cornelius,et al.  Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.

[40]  Vanja Dukic,et al.  Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[41]  F. Holmes,et al.  Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Umberto Veronesi,et al.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.

[43]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[44]  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials , 2022 .